Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766

Abrams P, Cardozo L, Khoury S, Wein A (2005) Incontinence, vol 2. Management Health Publication Ltd, Plymouth

Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817–820

Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169:2253–2256

Kaplan SA (2004) Use of muscarinic receptor antagonists as monotherapy in men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J Urol 171(Suppl):917 (abstract)

Lim E, Chia SJ (2005) Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? Neurourol Urodyn 24(5–6):205 (abstract)

Berges R, Dreikorn K, Höfner K, Jonas U, Laval KU, Madersbacher S, Michel MC, Muschter R, Oelke M, Pientka L, Tschuschke C, Tunn U (2003) Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS). Urologe A 42:584–590

Roehrborn CG (2006) Drug treatment for LUTS and BPH: new is not always better. Eur Urol 49:5–7

Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174:2273–2275 (discussion 2275–2276)

Saito H, Yamada T, Oshima H et al (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin in the benign prostatic hypertrophy with pollakiuria and/or urinary incontinence. Jpn J Urol Surg 12:525–536

Abrams P, Kaplan S, De Koning Gans HJ, Millard R (2006) Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175:999–1004 (discussion 1004)

Coyne KS, Matza LS, Thompson CL (2005) The responsiveness of the overactive bladder questionnaire (OAB-q). Qual Life Res 14:849–855

Roehrborn CG, McConnell JD, Barry MJ, Benaim E, Bruskewitz RC, Blute ML, Holtgrewe HL (2006) AUA guideline on the Management of Benign Prostatic Hyperplasia. http://www.auanet.org/guidelines/bph.cfm , Accessed June 19, 2006

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547–554

Michel MC, de la Rosette JJ, Piro M, Goepel M (2004) Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 172:601–604

Michel MC, Schneider T, Krege S, Goepel M (2002) Does gender or age affect the efficacy and safety of tolterodine? J Urol 168:1027–1031

Michel MC, de la Rosette JJ, Piro M, Schneider T (2005) Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol 48:110–115